Tonix制药控股 TNXP 深 沪
等待开盘 08-20 09:30:00 美东时间
12.73
+0.070
+0.55%
华盛通- 最 高13.16
- 今 开12.67
- 成交量 59.88万股
- 最 低 12.6264
- 昨 收 12.66
- 总市值 2.18亿
- 52周最高 31.55
- 市盈率 静 --
- 换手率 3.49%
- 52周最低 9.40
- 委 比 -49.70%
- 总股本 1715.10万
- 历史最高 13440000000.00
- 量 比 1.53
- 振 幅 4.21%
- 历史最低 9.40
- 每 手 1
- 风险率 5.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tonix Pharma Names CEO Seth Lederman Interim CMO
An announcement from Tonix Pharma ( ($TNXP) ) is now available. On August 18, 2...
08-19 04:36
财报速睇 | Tonix制药控股 2026财年Q2营收0.14亿美元，同比增长577.9%；归母净利润亏损0.41亿美元，同比亏损扩大43.4%
华盛资讯8月10日讯，Tonix制药控股公布2026财年Q2业绩，公司Q2营收0.14亿美元，同比增长577.9%，归母净利润亏损0.41亿美元，同比亏损扩大43.4%。
08-10 20:36
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
Tonix Pharmaceuticals Holding Corp. announced that its management team will participate in two investor conferences in August and September 2026. Seth Lederman, M.D., President and CEO, will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11 and attend 1x1 meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 16. Tonix is a biotech company focused on CNS disorders, infe...
08-05 11:00
Tonix Pharma Receives Official Minutes From Type C Meeting With FDA To Discuss Plans For Adaptive Phase 2 Field Study Of TNX-4800 To Prevent Lyme Disease In Adults In US
Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027 Long-acting monoclonal antibody TNX-4800 is a rapidly acting alternative to vaccination against Lyme disease with potential advantages in efficacy and tolerability over vacc...
08-03 19:11
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Tonix Pharmaceuticals Holding Corp. will host a conference call and webcast on August 10, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results and operational highlights. Registration links for the call and webcast are provided, with a replay available on the company’s website. Tonix, a commercial-stage biotech company, focuses on CNS disorders, infectious diseases, immunology, and rare diseases. Its flagship product, TONMYA...
07-27 11:00
Tonix Pharma Announces Publication Of Monkeypox Study In Journal Of Virology, Peer-Reviewed Publication Of ASM
Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreak Three new models for investigating mpox infection and pathogenesis identified Tonix is advancing TNX-801, a live, attenuated, minimally replicative investigational vaccine candidate based on...
07-15 21:07
Tonix Pharma expands Medicare coverage for TONMYA therapy
The latest announcement is out from Tonix Pharma ( ($TNXP) ). On July 13, 2026,...
07-13 19:54
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
Tonix Pharmaceuticals announced a major Medicare agreement for TONMYA, adding approximately 9 million Medicare lives (16% of 55 million Medicare beneficiaries in the U.S.) effective January 1, 2027. Combined with prior commercial payer agreements and Medicaid coverage, TONMYA will cover about 46% of all U.S. covered lives (145 million out of 314 million). The company is expanding its sales force, adding 50 new representatives by mid-third quarter...
07-13 11:00
